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H I G H L I G H T S
• Dissolving and transporting strongly
lipophilic drugs in body fluids is a
challenge.
• Highly hydrophobic drug Probucol
was dissolved in the micellar cores of a
copolymer.
• Chitosan was polymerized as a shell
around the micelles containing the
dissolved drug.
• The chitosan nano-shells were well-
formed, spherical and 30–300 nm in
diameter.
• They preserve the micelle integrity
and provide a pH-sensitive release
environment.
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A B S T R A C T
Chitosan is a very effective biopolymer for drug delivery purposes due to its biocompatibility, positive charge
and exceptionally pH sensitive degradability behavior in an aqueous medium. Nevertheless, its inability for
dissolving lipophilic drug active material and the difficulties in controlling the size and shape of the synthesized
particles in nanometer range are critical drawbacks in its effective use. In this study, a synthesis procedure which
addresses both issues simultaneously is presented. The procedure is based on initial dissolution of lipophilic drug
molecules within the hydrophobic cores of the micelles of a bio-compatible block-copolymer by ionic gelation
and subsequent formation of a chitosan shell by polymerization around the micellar structures.
Well-formed, hollow and perfectly spherical chitosan particles (nano-shells) in the 30–300 nm size range
could be successfully manufactured. Characterization by STEM, TEM, AFM, FTIR and DLS, DLS-LDV techniques
showed clearly that the drug was successfully incorporated into the chitosan structure. It was demonstrated that
the particles enveloped the micelle(s) of a Pluronic copolymer (P-123) whose hydrophobic cores contained a
strongly hydrophobic drug Probucol.
The chitosan nano-shells are expected to act as an agent protecting the integrity of the drug-loaded micelles in
the body fluid while providing a pH sensitive release medium. The drug uptake by the chitosan particles was
very high. A very sharp increase in the amount of the drug released with a slight change in the acidity of the
medium was an indication of the potential of the manufactured chitosan nano-shells as pH sensitive, target
specific delivery vehicles for drug release.
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1. Introduction
Natural polymers such as cellulose, starch, chitosan, carrageenan,
alginates etc. are among the preferred materials for drug delivery ap-
plications due to their chemically inert, nontoxic, biocompatible, bio-
degradable structures and availability. Among these materials, chit-
osan-based nanoparticles have been receiving special attention due to
their superior characteristics as i) high drug-carrying capacities, ii)
multi-functionality, ii) prolonged circulation and iv) favorable targeting
and penetrability of the cell membranes [1–8,10]. Grenha (2012) pre-
sents an excellent review of the methods for manufacturing chitosan
nanoparticles which can be grouped into the following categories:
emulsification and cross-linking [8,9], emulsion droplet coalescence
[11,12], emulsion solvent diffusion [13], reverse micellization [14–17],
ionic gelation [3,18–21], polyelectrolyte complexation [22–34], mod-
ified ionic gelation with radical polymerization [23,35,36] and deso-
lvation [37–40]. Despite this wide research base, complications still
exist in the synthesis of the chitosan nanoparticles due to their aversion
for uptaking and encapsulating lipophilic drug active materials and the
difficulties in controlling their size and morphology.
This study describes a reproducible and effective method to manu-
facture spherical, hollow, well-defined chitosan nanoparticles with a
micellar core which functions as a solvent for a completely water-in-
soluble drug. Due to this unique shape, the nanoparticles will also be
termed shelled nanoparticles or nano-shells interchangibly throughout
the text. The method comprises of two distinct stages which provide
superior control in both the drug loading and morphological properties
of the manufactured particles. Loading of the drug and creation of the
soft templates for subsequent particle formation are achieved in the first
stage. It is based on dissolution and encapsulation of the lipophilic drug
molecules within the hydrophobic cores of the micelles of a PEO-PPO-
PEO type three-block copolymer. The choice of the copolymer for this
paper was Pluronic P-123, but these polymeric surfactants, in general,
provide excellent opportunities for adjusting the solvation character-
istics due to their wide HLB range which can be exploited to vary the
concentration and density of the drug molecules loaded. Polymerization
of chitosan by cross-linking over the drug-loaded micelles to form
perfectly spherical nano-sized particles constitutes the second stage.
This stage provides outstanding flexibility for controlling the size and
morphology of the final particles and modifying their surface func-
tionality.
2. Materials and methods
2.1. Materials
A Pluronic type triblock copolymer (P-123) with relatively longer
hydrophobic blocks (PEO20-PPO65-PEO20) was employed to create the
template micelles. This copolymer was preferred due to its commercial
availability, biocompatibility, and safety [41,42].
The drug Probucol (PB) was employed for loading of the micelles.
Probucol is an anti-hyperlipidemic drug which functions by lowering
the cholesterol level in the blood by inhibiting cholesterol synthesis and
delaying cholesterol absorption. It is a white, odorless crystalline
powder with a melting point of 125 °C. It is freely soluble in chloroform,
benzene, ether, acetone, ethanol, methanol and acetonitrile; but com-
pletely insoluble in water. It must be stressed that selection of probucol
was solely due to its strong lipophilic characteristic in order to de-
monstrate that a completely water-insoluble drug active material could
be embedded within chitosan.
The other chemicals employed in the study were acetonitrile (AN)
for co-solving the drug with the block copolymer, sodium dodecyl
sulfate (SDS) for modification of the micelles, acetic acid (AA) for
chitosan dissolution and sodium tripolyphosphate (TPP) for chitosan
polymerization. All the chemicals were supplied by SIGMA-ALDRICH
chemical company and their most basic properties are presented in
Table 1. Ultra-pure water (18.2 MΩ) was used throughout the study.
The carbon grids and the mica surfaces for the transmission and
atomic force microscopy characterization work were provided by
“Micro to Nano” Innovative Microscopy Supplies Netherlands/(Value-
Tec-TEM-support-grids).
2.2. Method
The chitosan was precipitated in the form of a shell around the
surfactant micelles which were previously loaded with the lipophilic
drug. Hence, the procure consisted of two stages: the thin-film hydra-
tion step where the micelles were loaded with the drug and the ionic
gelation step where the chitosan was polymerized around the micelles.
A generalized flowsheet of the study is presented in Fig. 1.
In the initial phase, the P-123 micelles were dissolved together with
the water-insoluble drug in acetonitrile. Surface tension (ST) mea-
surements were employed to ensure that the P-123 molecules were in
the form of nearly spherical micelles. Subsequent evaporation of the
solvent generated an organic composite film of the polymer and the
drug. Hydration of this film in an aqueous phase forces the lipophilic
drug molecules energetically into the hydrophobic core of the micelles.
In this study, the aqueous phase was a solution of chitosan (0.5% by
weight) in an acetic acid solution (0.5% by volume). In some cases, the
micelles of P-123 were modified by SDS in order to control the size and
charge of the micellar structures. The aggregation number of the P-123
micelles is around 50 [43]; substitution of the relatively neutral P-123
structures with the smaller SDS molecules should lead to a compaction
of the micelle while introducing a negative charge [44]. A carbon grid
was dipped into an aliquot of the micellar solution and was dried and
kept under vacuum to prepare a representative sample for the were
transmission electron microscopy (TEM) characterization of the mi-
celles. The same procedure was repeated with a mica surface into the
micellar solution to prepare samples for the atomic force microscopy
(AFM) characterization of the micelles.
In the final phase, the micellar chitosan solution was reacted with a
cross-linking agent (TPP; 0.5% by weight) at a chitosan-TPP ratio of 1:1
to polymerize chitosan around the micelles as a shell. The presence of
acetic acid in the system ensures that the solution pH is maintained
around 4. Cross-linking of the chitosan molecules with TPP takes place
through the negatively charged oxygens in the TPP with the positively
charged amine groups on chitosan (Fig. 2) [45]. The precipitated par-
ticles are centrifuged and dried directly without any washing in vacuum
under ambient conditions. A schematic view of the chitosan nano-shells
manufactured is illustrated in Fig. 3. The figure shows only one micelle
in the structure; however, more than one micelle can also be enveloped
by the chitosan cell.
Prior to the characterization studies, the amount of the probucol
which was enveloped within the chitosan structure was estimated by
measuring the amount of probucol in the centrifuge supernatant with
UV–vis spectroscopy [46]. The dried chitosan nanoparticles were
characterized using scanning transmission electron microscopy (STEM),
dynamic light scattering (DLS), dynamic light scattering with laser
velocimetry (DLS-LV), Fourier transform infrared spectroscopy (FTIR).
A list of all the characterization methods employed in this study is
summarized in Table 2.
For the preliminary drug release tests, the dried particles were
dispersed (0.4% by weight) in simulated body fluids [47] of different
pH values of 6.8 and 7.4 and the amount of drug released into the
solution was checked using UV–vis spectroscopy [46,48].
3. Results and discussion
3.1. Characterization of the P-123 micelles
Fig. 4 gives the results of surface tension measurements of P-123
solutions. The surface tension measurements were performed to
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determine the association behavior of the P-123 molecules in aqueous
solution. The graph demonstrates that the surface tension-concentra-
tion profiles of the P-123 solutions could roughly be divided into 3
distinct regions: In Region I, the surface tension decreases steadily with
increasing concentration. In this region, the molecules of the copolymer
are in monomer form. Region II is a transition region marked by a
shallower slope indicating the initiation of aggregation where the co-
polymer molecules start to form dimers, trimers, etc. progressively. The
molecules aggregate in the form of full grown micelles in Region III and
the surface tension remains constant with changes in concentration.
The CMC value of P-123 could be determined from the interception
between Regions II and III and it was found to be around 5 × 10−5 M.
Fig. 5 presents the three repeat size distributions of the P-123 mi-
celles by dynamic light scattering at a concentration of 10−3 M. The
reason for selecting this concentration is the fact that it is well-past the
CMC but low enough to generate tight, spherical since a transition from
spherical to cylindrical form begins to take place at around 10−2 M
[49]. It can be seen from the graph that the micelle size varies between
8 and 40 nm. The d50 median size for the distribution is around 20 nm.
The size and shape of the micelles at this concentration were also
investigated using atomic force microscopy and scanning transmission
electron microscopy and the images obtained are presented in Fig. 6.
The results of the AFM and STEM imaging confirm the average micelle
size indicated by DLS. The images also demonstrate that the micelles
formed were closer to a spherical shape as expected.
3.2. Modification of the P-123 micelles by SDS
It has been shown previously that addition of smaller, anionic sur-
factant molecules into a solution of P-123 resulted in mixed micelles via
hydrophobic association of the surfactant with the block copolymer
micelles resulting in smaller and negatively charged copolymer micelles
(Bhattacharjee, 2013). In this study, the surfactant employed for the
modification of the micelle size of the copolymer P-123 was the simple
anionic surfactant sodium dodecyl sulfate (SDS). It was confirmed that
the solubilization of the hydrocarbon chains of the smaller SDS into the
polypropylene oxide core of the P-123 resulted in a steady decrease in
the size of the micelles with an increase in the concentration of the
anionic surfactant. The method provides the means of controlling the
size of the chitosan nano-shells which are formed around the copoly-
meric surfactant micelles. Some representative size measurement re-
sults obtained with DLS are presented in Fig. 7 showing the size dis-
tribution of the micelles of pure SDS, pure P-123, and SDS + P-123
mixture. It can be seen that the median size of the micelles of the an-
ionic SDS was much smaller, around 1.5 nm compared to the median
size of 20 nm for the P-123 micelles. However, when the anionic sur-
factant was mixed to the copolymer, the micelles of the mixed system
were significantly smaller with a median size of around 5 nm. This
suggests that the SDS molecules were incorporated into the structure of
the P-123 micelles and resulted in a more compact structure. The lack
of a bimodal distribution for the SDS + P-123 mixture is indicative of
the fact that the SDS molecules were not present as separate micelles
but were incorporated into the micellar structure of the P-123 copo-
lymer.
Table 1
Basic properties of the materials and chemicals employed in the study.
Name/Formula Chemical Structure MW g/mole
Chitosan (CS) 28,000
N-acetyl-D-glucosamide
DD%: 75–85
Sodium tripolyphosphate 367.8
(TPP)
Na5P3O10
PEO-PO-PEO copolymer 5800
(P-123)
HO(EO)20(PO)70(EO)20H
Sodium dodecyl sulfate 288.4
(SDS)
Na-C12H25SO4
Probucol (PB) 516.8
C31H48O2S2
Acetonitrile (AN) 41.1
CH3CN
Acetic Acid (AA) 60.1
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The zeta potentials of the micelles under the same conditions were
determined by DLS-LV and are presented in Fig. 8 for the same solutions
presented in Fig. 7. The figure shows that the micelles of the anionic
SDS were charged negatively with a median zeta potential of around
−32 mV. The micelles of the P-123 were charged to a much less degree
with a median zeta potential of around−12 mV. The surface charge of
the mixed micelles of the binary SDS + P-123 mixture was negatively
charged with a median zeta potential of around −22 mV, confirming
that the SDS molecules were incorporated into the structures of the P-
123 micelles.
3.3. Characterization of the drug-loaded P-123 micelles
The P-123 micelles were loaded with a lyophilic drug probucol by
thin-film hydration method described above. Characterization of the
drug-loaded micelles was done by STEM and TEM. The STEM images of
Fig. 1. Flowsheet of the method used to create
chitosan nanoparticles embedded with P-123 mi-
celles encapsulating the lipophilic drug in the mi-
cellar core.
Fig. 2. The mechanism of cross-linking of chitosan by TPP.
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the drug-loaded P-123 micelles are presented in Fig. 9 (right) along
with the images of the blank P-123 micelles in the absence of probucol
(left) for comparison. A more detailed TEM image of the drug-loaded P-
123 micelles are presented in Fig. 10.
The STEM images clearly show that the size of the P-123 micelles
Fig. 3. The schematic structure of a micelle-embedded chitosan nanoparticle.
Table 2
Characterization methods used in this study.
Analysis Method Device
Micellar Size DLS Malvern Zetasizer Nano ZS
Micellar Charge DLS-LDV Malvern Zetasizer Nano ZS
Micellar morphology AFM-Tapping mode Digital Inst. Nanoscope IV
Particle morphology STEM Quanta 250 SEM
Inner morphology TEM FEI Tecnai G2 Spirit Bio Twin
Particle composition FTIR Perkin Elmer
Surface tension Dü Noüy Ring Krüss Tensiometer K10ST
Drug Release UV–vis Varian Cary 50 UV
Fig. 4. Surface tension data for the aqueous solutions of P-123.
Fig. 5. Size distribution of the P-123 micelles in 10–3 M aqueous P-123 solutions.
Fig. 6. The AFM (top) and STEM (bottom) images showing the size and morphology of
the P-123 micelles at 10–3 M aqueous P-123 solution.
Fig. 7. Size distribution of the micelles of aqeous SDS, P-123 and SDS + P-123 solutions.
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increases significantly when the drug probucol is loaded into the mi-
celle structure. The STEM images also demonstrate that the spherical
shape of the micelles is preserved after the loading of the drug. Also, the
relatively narrow size distribution of the micelles becomes wider when
the drug is incorporated into the micellar structure. The TEM images of
the loaded micelles display the drug in the micellar structure very
clearly and confirm both the shape and the range of sizes for the mi-
celles generated in the AFM, STEM and DLS studies.
3.4. Characterization of the hollow chitosan nanoparticles (nano-shells)
encapslating the probucol-loaded P-123 micelles
In this part of the study, the lipophilic drug probucol was in-
corporated into the chitosan structure by cross-linking the chitosan
around the drug-loaded formed micelles using the ionic gelation pro-
cedure. The final product was in the form of nanoparticles which
comprised of a chitosan shell around the P-123 micelles which contain
probucol dissolved in the hydrophobic core (see Fig. 3). The particles
synthesized were characterized by STEM, FTIR, and DLS-LDV analyses.
The CS/TPP ratio, CS%, and TPP solution percent were kept constant at
unity in the manufacturing of the particles subjected to these analyses
though they could be varied to manipulate the size of the nanoparticles
produced. The STEM images of the shelled chitosan nanoparticles are
presented in Fig. 11. The figure shows that chitosan particles of sphe-
rical shape and excellent consistency could be produced successfully. It
can be observed from the figure that the size of the chitosan particles
ranged from 30 to 300 nm. The presence of 30 nanometer particles
indicate that some chitosan shells envelope only a single micelle while
the relatively wide size distribution suggests that in some cases chitosan
may have precipitated around more than one loaded P-123 micelle.
The zeta potentials of the chitosan nano-shells precipitated around
the loaded P-123 micelles were measured and presented in Fig. 12 to-
gether with the zeta potential of the chitosan particles cross-linked
without any copolymer or drug in the system. The precipitated particles
were washed and dispersed in distilled water prior to the zeta potential
measurements. The two charge distributions are almost very similar,
indicating that the micelles of the copolymer P-123 were enveloped
within the chitosan shells to a large degree.
The structure of the chitosan nanoparticles with enveloped micelles
which contained probucol was further investigated by FTIR analysis.
The FTIR spectrum of the chitosan nanoparticles is presented together
Fig. 8. Zeta Potential distribution of the micelles of aqeous SDS, P-123 and SDS + P-123
solutions.
Fig. 9. The STEM images of the P-123 micelles
without (left) and loaded with the drug probucol
(right) in the structure at the same magnification.
Fig. 10. TEM images of the P-123 micelles loaded with the drug probucol.
Fig. 11. The STEM images of the shelled chitosan nanoparticles (nano-shells) loaded with
the P-123 micelles containing the dissolved Probucol.
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with the spectrums of the pure chitosan (Pure CS), cross-linked chitosan
(CS + TPP), pure P-123 and pure probucol in Fig. 13 for comparison.
The characteristic peaks obtained for pure forms of chitosan, P-123 and
probucol were in very good agreement with the spectra in the literature
[50–54].
The absorption bands at 1653 and 3450 cm−1 are ascribed to NeH
bending in the primary amine of pure chitosan. The intensity of these
peaks decreases significantly after polymerization with TPP most
probably due to the linkage between tri polyphosphoric groups of TPP
and ammonium groups of chitosan. Though it is not presented in Fig. 13
for clarity, TPP also has a very sharp characteristic peak for the P-O-P
band at 892 cm−1. The disappearance of this band in the CS + TPP
system is another indication of successful cross-linking between the
negatively charged oxygen and the positively charged ammonium
groups (see Fig. 2). Furthermore, the appearance of the P = O band at
1140–1250 cm−1 in the chitosan + TPP system which is non-existent
in the pure chitosan spectra is yet another indication since double-
bonded oxygen does not make any bonds with the chitosan.
Probucol and P-123 spectra show several sharp, overlapping char-
acteristic peaks in the 500–1500 and 2800–3000 cm−1 regions which
complicate the analysis since the appearance of these peaks in the
spectra of the micelle-loaded chitosan nano-shells can mean either P-
123 or probucol is in the structure. However, some peaks which appear
in the spectra of the nanoparticles are specific to either P-123 or pro-
bucol. For example, the peaks at 2890, 1375, 1120 and 910 cm−1 are
specific only to P-123. Similarly, the strong peaks at 1422, 1310 and
1275 cm−1 are specific to probucol. The fact that all these peaks are
present in the spectra of the loaded chitosan nano-shells clearly indicate
that not only P-123, but also probucol is present in the structure.
3.5. The uptake of probucol and preliminary release tests
Prior to the release studies, the amount of the probucol which was
enveloped within the chitosan structure was estimated by deducting the
amount of probucol in the centrifuge supernatant from the original
probucol amount in the system [46]. The uptake in two repeat tests was
found to be very high; 86.7% and 93.4% of the initial probucol amount.
The release tests were carried out with a known amount of dried chit-
osan particles dispersed (0.4% by weight) in simulated body fluid [47]
of different pH values (pH 6.8 and 7.4). These pH values were re-
presentative of the acidic environment of cancerous and healthy cells,
respectively [55]. The amount of drug released into the solution was
checked using UV–vis spectroscopy.
Two repeat tests were carried out at the specified pH values and the
results are presented in Fig. 14. It can be seen that the release is very
pH-specific. Under the pH conditions predominant with the healthy
cells, a release of about 10% takes place within the first hour and no
more drug release is observed. The reason for this initial release is most
probably due to the release of the residual micelle-probucol structures
which have not been enveloped within the chitosan shells but remained
in the solution and clung to the surfaces of the chitosan particles during
centrifuging and drying step since no washing was applied to the cen-
trifuged particles. The same initial release was also observed at the
acidic pH value of 6.8, but it was slightly higher at around 12%. The
reason for the slightly higher release was most probably due to the
Fig. 12. Zeta potential measurements of the chitosan nano-shells with and without the P-
123 micelles.
Fig. 13. FTIR results of the chitosan nanoparticles embedded with the drug loaded P-123
micelles.
Fig. 14. The preliminary drug release data showing the release of the drug probucol from
the chitosan nanoparticles dispersed in the simulated body fluid at two different pH.
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additional release of the drug from inside the chitosan particles due to
the initiation of chitosan degradation at this acidic pH. The release
continued in an accelerated fashion and reached 75% after 36 h. The
difference in the release profiles between pH 6.8 and pH 7.4 is very
drastic and demonstrates simultaneously the presence of the drug
within the chitosan nano-shells as well as the potential of the shelled
chitosan nanoparticles as pH sensitive, target specific delivery vehicles
for drug release.
4. Conclusions
In this study, a strongly lipophilic drug (Probucol) was embedded
inside hollow, spherical, nano-sized chitosan particles (nano-shells) by
combining the thin-film hydration and ionic gelation techniques. The
procedure was based on first dissolving the drug in the hydrophobic
core of the micelles of a biocompatible copolymer (P-123) by ionic
gelation and subsequent cross-linking of the chitosan molecules around
the micellar soft-templates by ionic gelation. The product was well-
formed, hollow and perfectly spherical chitosan nanoparticles (nano-
shells) in the size range of 30–300 nm.
The manufactured nanoparticles were characterized using scanning
transmission and transmission electron microscopy, atomic force mi-
croscopy, dynamic light scattering, dynamic light scattering with laser
velocimetry, Fourier transform infrared spectroscopy and surface ten-
sion analyses. The study has shown that:
• the strongly lipophilic drug probucol was successfully dissolved in
the cores of the micelles of a PEO-PPO-PEO triblock copolymer
(Pluronic P-123) using thin-film hydration method.
• Polymerization of the chitosan around the micelles by ionic gelation
allowed incorporating this lipophilic drug into the structure of
chitosan successfully. The final product was in the form of well-
formed, nano-sized, spherical and hollow chitosan particles
• the procedure provides a very good control on the size and mor-
phology of the particles manufactured as well as controlling the
amount of the drug loading.
• The drug uptake by the chitosan nanoparticles was very high. Two
repeat tests demonstrated that 86.7% and 93.4% of the initial pro-
bucol amount was incorporated into the chitosan structure.
• The preliminary release tests demonstrated that there was no ap-
preciable release at pH 7.4 where the integrity of the chitosan shells
should be preserved. The drastic increase in the release amounts at
the acidic pH of 6.8 proved simultaneously the presence of the drug
within the particles as well as their potential as pH sensitive, target
specific delivery vehicles for drug release.
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